Synthesis and preclinical characterization of [64Cu]NODAGA-MAL-exendin-4 with a Nε-maleoyl-l-lysyl-glycine linkage

Nuclear Medicine and Biology

Volumn 40, Issue 8, 2013, Pages 1006-1012

  Yim, Cheng Bin ^a,b   Mikkola, Kirsi ^a   Fagerholm, Veronica ^a   Elomaa, Viki Veikko ^a   Ishizu, Tamiko ^a   Rajander, Johan ^c   Schlesinger, Joern ^a   Roivainen, Anne ^a,b   Nuutila, Pirjo ^a   Solin, Olof ^a,c  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c ÅBO AKADEMI UNIVERSITY   (Finland)

Author keywords

Copper 64; Exendin; GLP 1 receptor; NODAGA; Renal brush border membrane

Indexed keywords

COPPER (1,47 TRIAZACYCLONONANE 1 GLUTAMIC ACID 4,7 DIACETIC ACID) EXENDIN 4 C 64; COPPER (1,47 TRIAZACYCLONONANE 1 GLUTAMIC ACID 4,7 DIACETIC ACID) N EPSILON MALEOYLLYSYLGLYCINE EXENDIN 4 CONJUGATE C 64; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BIOACCUMULATION; COMPLEX FORMATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG STABILITY; DRUG SYNTHESIS; DRUG UPTAKE; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIPOPHILICITY; MALE; MICHAEL ADDITION; NONHUMAN; RADIOACTIVITY; RADIOASSAY; RADIOISOTOPE DISTRIBUTION; RAT; TISSUE DISTRIBUTION;

COPPER-64; EXENDIN; GLP-1 RECEPTOR; NODAGA; RENAL BRUSH BORDER MEMBRANE;

ACETATES; ANIMALS; AUTORADIOGRAPHY; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG STABILITY; GLYCINE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; ISOTOPE LABELING; KINETICS; MALE; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RATS; VENOMS;

EID: 84886295228     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.06.012     Document Type: Article

References (47)

1. Naucka M.A., Meier J.J. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005, 128:135-148.
2. Holst J.J. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006, 49:253-260.
3. 2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 2006, 47:2025-2033.
4. Wild D., Mäcke H., Christ E., Gloor B., Reubi J.C. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med 2008, 359:766-768.
5. Wild D., Wicki A., Mansi R., Béhé M., Keil B., Bernhardt P., et al. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med 2010, 51:1059-1067.
6. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging 2010, 37:1345-1355.
7. 40-exendin-4 by targeting GLP-1 receptor. Bioconjugate Chem 2011, 22:1587-1594.
8. 18F-FBEM-EM3106B, a new GLP-1 analogue. Mol Pharm 2011, 8:1775-1782.
9. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. Eur J Nucl Med Mol Imaging 2012, 39:463-473.
10. 18F]AlF-NOTA analog of exendin-4 for imaging of GLP-1 receptor in insulinoma. Theranostics 2012, 2:999-1009.
11. Melis M., Valkema R., Krenning E.P., de Jong M. Reduction of renal uptake of radiolabeled octreotate by amifostine coadministration. J Nucl Med 2012, 53:749-753.
12. Vegt E., Eek A., Oyen W.J.G., de Jong M., Gotthardt M., Boerman O.C. Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides. Eur J Nucl Med Mol Imaging 2010, 37:226-234.
13. Behr T.M., Goldenberg D.M., Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998, 25:201-212.
14. Arano Y., Fujioka Y., Akizawa H., Ono M., Uehara T., Wakisaka K., et al. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Cancer Res 1999, 59:128-134.
15. Nakamoto Y., Sakahara H., Saga T., Sato N., Zhao S., Arano Y., et al. A novel immunoscintigraphy technique using metabolizable linker with angiotensin II treatment. Br J Cancer 1999, 79:1794-1799.
16. Akizawa H., Arano Y. Altering pharmacokinetics of radiolabeled antibodies by the interposition of metabolizable linkages. Metabolizable linkers and pharmacokinetics of monoclonal antibodies. Q J Nucl Med 2002, 46:206-223.
17. ε-maleoyl-L-lysine (HML)-conjugated Fab fragments. Bioconjugate Chem 2001, 12:178-185.
18. Fujioka Y., Satake S., Uehara T., Mukai T., Akizawa H., Ogawa K., et al. In vitro system to estimate renal brush border enzyme-mediated cleavage of peptide linkages for designing radiolabeled antibody fragments of low renal radioactivity levels. Bioconjugate Chem 2005, 16:1610-1616.
19. Kukis D.L., Li M., Meares C.F. Selectivity of antibody-chelate conjugates for binding copper in the presence of competing metals. Inorg Chem 1993, 32:3981-3982.
20. Kukis D.L., Diril H., Greiner D.P., DeNardo S.J., DeNardo G.L., Salako Q.A., et al. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer (Suppl) 1994, 73:779-786.
21. 64Cu-labeled bifunctional chelate-bombesin conjugates. Bioconjugate Chem 2011, 22:1729-1735.
22. De Silva R.A., Jain S., Lears K.A., Chong H.S., Kang C.S., Sun X., et al. Copper-64 radiolabeling and biological evaluation of bifunctional chelators for radiopharmaceutical development. Nucl Med Biol 2012, 39:1099-1104.
23. 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med 2011, 52:1110-1118.
24. 2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci USA 2007, 104:12462-12467.
25. 64Cu using a biomedical cyclotron. Nucl Med Biol 1997, 24:35-43.
26. Smith S.V. Molecular imaging with copper-64. J Inorg Biochem 2004, 98:1874-1901.
27. 64Ni nuclei. Appl Radiat Isot 2007, 65:1115-1120.
28. Rajander J., Schlesinger J., Avila-Rodriguez M.A., Solin O. Increasing specific activity in Cu-64 production by reprocessing the Ni-64 target material. J Labelled Comp Radiopharm 2009, 52(S1):234.
29. Fields G.B., Noble R.L. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 1990, 35:161-214.
30. Kaiser E., Colescott R.L., Bossinger C.D., Cook P.I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem 1970, 34:595-598.
31. Meienhofer J., Waki M., Heimer E.P., Lambros T.J., Makofske R.C., Chang C.-D. Solid phase synthesis without repetitive acidolysis. Preparation of leucyl-alanyl-glycyl-valine using 9-fluorenylmethyloxycarbonylamino acids. Int J Pept Protein Res 1979, 13:35-42.
32. Lewis M.R., Shively J.E. Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions. Bioconjugate Chem 1998, 9:72-86.
33. Mikkola K, Yim C-B, Fagerholm V, Ishizu T, Elomaa V-V, Rajander J, et al. Comparison of 64Cu- and 68Ga-labelled [Nle14, Lys40(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta-cell imaging in rodents. Submitted.
34. Duncan J.R., Welch M.J. Intracellular metabolism of indium-111-DTPA labeled receptor targeted proteins. J Nucl Med 1993, 34:1728-1738.
35. Duncan J.R., Behr T.M., DeNardo S. Intracellular fate of radiometals. J Nucl Med 1997, 38:829.
36. Inui K.I., Masuda S., Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int 2000, 58:944-958.
37. Akizawa H., Uehara T., Arano Y. Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv Drug Deliv Rev 2008, 60:1319-1328.
38. Simonsen L., Holst J.J., Deacon C.F. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 2006, 49:706-712.
39. 125I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention. Bioconjugate Chem 2011, 22:1089-1102.
40. Mueller B.M., Wrasidlo W.A., Reisfeld R.A. Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers. Bioconjugate Chem 1990, 1:325-330.
41. Kaneko T., Willner D., Monkovic I., Knipe J.O., Braslawsky G.R., Greenfield R.S., et al. New hydrazone derivatives of adriamycin and their immunoconjugates - a correlation between acid stability and cytotoxicity. Bioconjugate Chem 1991, 2:133-141.
42. Sirich T.L., Aronov P.A., Plummer N.S., Hostetter T.H., Meyer T.W. Numerous protein-bound solutes are cleared by the kidney with high efficiency. Kidney Int 2013, 10.1038/ki.2013.154.
43. Smith H.W., Finkelstein N., Aliminosa L., Crawford B., Graber M. The renal clearances of substituted hippuric acid derivatives and other aromatic acids in dog and man. J Clin Invest 1945, 24:388-404.
44. 188Re]organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levels. Bioconjugate Chem 2007, 18:190-198.
45. Akizawa H., Imajima M., Hanaoka H., Uehara T., Satake S., Arano Y. Renal brush border enzyme-cleavable linkages for low renal radioactivity levels of radiolabeled antibody fragments. Bioconjugate Chem 2013, 24:291-299.
46. Gotthardt M., van Eerd-Vismale J., Oyen W.J.G., de Jong M., Zhang H., Rolleman E., et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 2007, 48:596-601.
47. Vegt E., Melis M., Eek A., de Visser M., Brom M., Oyen W.J.G., et al. Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging 2011, 38:623-632.